Calcium 2-aminoethylphosphate:Exports & Compliance White Paper 2026

I. Executive Summary

Calcium 2-aminoethylphosphate (CAS 10389-08-9), the calcium salt of O-phosphorylethanolamine, is supplied as a fine chemical and research material. It must be stated plainly at the outset: this compound has no approved therapeutic indication in any major jurisdiction. It is offered strictly as RUO (Research Use Only) material for laboratory, analytical and process-development use, is not for human or veterinary use, and is not a finished consumer or dietary product. Suppliers should note that phosphorylethanolamine has been the subject of unapproved and controversial "compound" claims in some markets; those claims are not endorsed here.

Chemically the material is a phosphate monoester salt of a primary amino alcohol, and its specification is dominated by stoichiometry rather than a single assay figure. Calcium and phosphorus content, the Ca:P ratio, free ethanolamine, inorganic phosphate and water must be reported together, because a nominally correct salt can still be a mixture of mono- and di-calcium forms, free acid and occluded inorganic phosphate. The substance is hygroscopic and water-soluble, so moisture control is a specification issue rather than a handling nicety.

This paper is written from a CDMO perspective: phosphorylation route classes at class level, salt-form and stoichiometry control, analytical method development and validation, RUO-grade versus development and GMP-grade campaigns, containment, ICH Q7 and Q11 where applicable, ICH Q3D elemental impurities, ISO 9001, Know-Your-Customer and end-use declaration, and the China, India and Western fine-chemical ecosystem. No dosing, health or disease claim is made in this document.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

Phosphorylethanolamine is a naturally occurring phosphorylated amino alcohol, an intermediate of the Kennedy pathway for phosphatidylethanolamine biosynthesis. For a research-material supplier that pathway defines the legitimate contexts of use — enzyme and pathway studies, metabolomics and reference-standard work — and the related substances a specification must separate: ethanolamine, inorganic phosphate and pyrophosphate. Nothing here characterises the material as a therapeutic agent.

• Phosphate monoester and calcium-salt speciation: The molecule is a zwitterionic phosphate monoester with a primary amine, and calcium binding is pH-dependent, so different precipitation and neutralisation conditions give different solids. A lot can contain mono-calcium and di-calcium forms, free acid and occluded inorganic phosphate, which is why the Ca:P molar ratio is a better identity test than calcium content alone. ICP-OES for calcium with ion chromatography and 31P-NMR speciation is the standard combination.
• Hygroscopicity, water content and aqueous stability: The salt is hygroscopic and freely soluble in water, so water content drifts with ambient relative humidity unless packaging is genuinely moisture-tight. Karl Fischer titration, loss on drying and a water-activity check on release are standard. In solution the ester can hydrolyse at pH extremes and the medium supports microbial growth, so material is supplied dry.

2.2 Synthesis and Manufacturing Technologies

Two phosphorylation route classes dominate supply, and the choice between them is driven by the grade being sold. Both are described at route-class level only; operating conditions belong to the manufacturer's process documentation and to tech-transfer agreements.

• Chemical phosphorylation, phosphorus oxychloride route class: The classical approach phosphorylates ethanolamine, with the amine protected or protonated, using phosphorus oxychloride in a trialkyl phosphate medium or with a tertiary amine as acid scavenger, then hydrolyses and converts to the calcium salt with calcium hydroxide or carbonate. The characteristic impurity set is unreacted ethanolamine, inorganic phosphate, chloride, pyrophosphate species and colour bodies. Purification relies on pH-controlled precipitation, ion-exchange or charcoal treatment and crystallisation.
• Enzymatic phosphorylation, kinase route class: The alternative uses an ethanolamine kinase or broader phosphotransferase with ATP and a regeneration system, as isolated enzyme or whole-cell biocatalysis. The attraction is regioselectivity and absence of chlorinated phosphorus reagents; the cost is lower productivity and a downstream that must clear protein, host-cell DNA and endotoxin. RUO campaigns favour it where a customer wants material free of chlorinated reagent residues.

2.3 Core Application Matrix

• Biochemical and cell-biology research reagent (RUO): Legitimate use is as a reagent in phospholipid biosynthesis and Kennedy-pathway research, in enzyme assays and substrate or inhibitor screening, and in cell-culture media development by qualified laboratories. Supply is made on the basis that the buyer is a research organisation and that material is handled by trained personnel under laboratory controls.
• Analytical reference standard and method development: A substantial share of demand is for characterised material used to build and validate methods: ion chromatography for phosphate species, LC-MS/MS and 31P-NMR for identity and assay, ICP-OES for calcium and elemental impurities. These customers need a defined assay value, stated uncertainty and a documented batch record rather than a commodity certificate.
• Custom synthesis and nutritional-research ingredient development: CDMO partners commission salt-form screening, stoichiometric variants, labelled analogues and scale-up studies. Where a customer's intended end use is nutritional research, the supplier still delivers research material under RUO terms and does not supply a finished consumer or dietary product; food-law assessment of any finished article rests with the customer.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is institutional: academic and industrial phospholipid research, metabolomics core facilities and CDMO process-development projects. It is small in tonnage, lumpy in timing and sensitive to reputation rather than price, because the compound has attracted unapproved "compound" marketing in some markets. The practical consequence for 2026 sourcing is that buyers have tightened qualification: they ask for end-use declarations, documented RUO labelling and a specification stating stoichiometry explicitly, and they avoid suppliers who blur the line between a research reagent and a consumer article.

3.2 Capacity Distribution and Export Flows

Capacity sits where phosphate-ester chemistry is established: Chinese and Indian plants with POCl3 handling, aqueous precipitation and ion-exchange trains, plus Western and Japanese specialists running biocatalytic and high-purity campaigns. Export flows are dominated by small lots — grams to a few kilograms — moving by air freight or courier, frequently through research-catalogue distributors that re-label and hold inventory. Larger development campaigns move by sea in drums under moisture-controlled packaging.

3.3 Market Bifurcation and Pricing Dynamics

The market divides into catalogue-grade and development-grade material. Catalogue prices reflect small-lot analytical cost and distributor margin and are largely insensitive to raw-material cost. Development-grade pricing is driven by campaign cost: purification train time, elemental-impurity and microbiological testing, documentation, and for GMP-aligned work cleaning validation and dedicated equipment. Quotations are project-based, and price moves with the analytical package requested rather than with volume.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

The compliance perimeter is chemical and commercial rather than therapeutic. There is no marketing authorisation to hold, so what governs supply is substance-level chemical regulation, quality-system discipline, correct RUO labelling and end-use control. Suppliers who treat the material as a consumer ingredient, or who allow customers to present it as one, take on risk no certificate of analysis can mitigate.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH registration, CLP classification and poison-centre notification: Placement on the EU market requires registration under Regulation (EC) No 1907/2007 at the applicable tonnage band, with a non-EU exporter relying on an only representative; classification, labelling and packaging under Regulation (EC) No 1272/2008; a safety data sheet in the language of the member state; and, where triggered, Annex VIII poison-centre notification. Buyers should confirm the registration number rather than accept an undocumented "REACH compliant" statement.
• The research-use boundary in food law: Material sold as RUO must not be presented, labelled or documented as a food supplement, food ingredient or medicinal product. If a customer intends a food use, that use falls under Directive 2002/46/EC and, unless significant consumption in the Union before 15 May 1997 can be documented, under the novel-food regime of Regulation (EU) 2015/2283 — an assessment for the food business operator, not the chemical supplier. The unapproved "compound" claims made about phosphorylethanolamine in certain markets are not endorsed.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA inventory status and EPA expectations: Commercial import requires the substance to be listed as active on the TSCA inventory, or covered by a bona fide research-and-development or other applicable exemption; a new use may require a premanufacture notice or significant-new-use-rule assessment. A mis-declared shipment is a customs and enforcement problem rather than a commercial one. HazCom 2012 labelling and a compliant safety data sheet apply in parallel.
• FDA perimeter — no approved indication, RUO labelling: The compound holds no approved new drug or abbreviated application and is not an approved animal drug or listed food additive, so any representation of therapeutic benefit is outside the lawful perimeter. Research-use-only labelling must be unambiguous on the label, the safety data sheet and the quotation, and must state that the material is not for human or veterinary use and not a finished consumer or dietary product.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

The environmental profile of this chemistry is set by phosphorus. Effluent phosphate drives eutrophication, discharge consent limits are tight in most jurisdictions, and the chlorinated route class adds a halide and solvent load that must be captured rather than diluted. Auditing customers increasingly ask specifically about phosphate in effluent rather than about generic certifications.

5.1 Carbon Footprint and Circular Economy

Because the process is largely aqueous and the product is isolated by precipitation and drying, energy concentrates in concentration, drying and solvent recovery, and the largest waste stream is phosphate-containing mother liquor. Sites certified to ISO 14001 normally report phosphate removal or recovery, effluent chemical oxygen demand, solvent recovery and energy per kilogram released — the figures a Scope 3 assessment actually needs. The enzymatic route class reduces halide and solvent load but adds a biological waste stream requiring inactivation.

5.2 Sustainable Sourcing and Traceability

Ethanolamine and phosphorus raw materials are petrochemical and mineral respectively, and buyers ask for origin and impurity disclosure rather than agricultural traceability. Because the material is often used in cell-based research, vegan and animal-component-free statements, halal and kosher certification where requested, and non-GMO declarations are frequent qualification requirements. ISO 9001, REACH SVHC screening and documented supply-chain due diligence complete the file.

VI. Supply Chain Resilience and Export Logistics

The molecule is a hygroscopic, water-soluble solid shipped in small lots, and the logistics problem is moisture rather than hazard. Material arriving caked, or above its water specification, is the most common cause of rejection and is almost always a packaging or transit-humidity failure.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture-barrier primary packaging: Standard practice is a double polyethylene liner inside a high-density polyethylene or fibre drum, heat-sealed with desiccant and closed under controlled relative humidity. Liner water-vapour transmission should be stated and matched to transit duration. Research-scale packs are typically amber glass or aluminium laminate pouches with individual desiccant sachets.
• Dispensing, labelling and contamination control: Weighing and sub-packaging should be done in a low-humidity environment, since the material picks up moisture quickly once opened, and customers should re-test water content after opening. Labels must carry the RUO statement, the not-for-human-or-veterinary-use statement and the correct CLP or HazCom pictograms where classification requires them.

6.2 Dangerous Goods Identification and Transit Protocols

Most consignments are not dangerous goods for transport: the substance is not flammable, oxidising or acutely toxic, and where a classification applies it is typically irritation rather than systemic toxicity, which does not trigger a UN class assignment. Classification must nonetheless come from the current safety data sheet and the current adaptation to technical progress of the CLP Regulation rather than be assumed. Ambient transport with moisture protection is normal, and long humid sea lanes should be avoided unless container desiccant levels are specified.

VII. Enterprise Global Expansion Strategy Guide

Suppliers who succeed here sell analytical credibility and disciplined end-use control. The buyers are research institutions, pharmaceutical and biotechnology process-development groups and catalogue distributors, and their questions concern specification content and documentation rather than unit price.

1. Sell the analytical package, not just the powder: Offer a specification reporting calcium and phosphorus content, the Ca:P ratio, assay by ion chromatography or LC, free ethanolamine, inorganic phosphate, water by Karl Fischer, heavy metals to ICH Q3D-style limits and microbial limits. Validate methods to ICH Q2 or equivalent and hold retention samples.
2. Run RUO-grade and development or GMP-grade campaigns separately: Keep the two on different documentation and, where practical, different equipment, applying ICH Q7 and Q11 to the development campaign with a defined control strategy, cleaning validation and change control. Containment and operator exposure assessment come first where the enzymatic or chlorinated route is used.
3. Make KYC and end-use declaration a commercial control: Screen every buyer, require a signed declaration of research or industrial end use, decline orders indicating consumer, supplement or self-administration channels, and keep records under ISO 9001 document control. This is the most effective protection against the exposure this molecule carries.

VIII. Conclusion

Calcium 2-aminoethylphosphate is a small, technically exacting research chemical whose commercial difficulty lies in specification honesty and end-use discipline. The compound has no approved therapeutic indication and is supplied only as RUO material, not for human or veterinary use and not as a finished consumer or dietary product, and the unapproved "compound" claims about phosphorylethanolamine in some markets are not endorsed. Suppliers who hold that line, and who document stoichiometry rather than a single assay number, are the ones research and CDMO buyers will qualify.

Into 2026 the direction of travel is stricter buyer qualification, more explicit RUO documentation, tighter elemental-impurity expectations driven by cell-based research and continued pressure on phosphate-bearing effluent. Organisations investing in validated methods, moisture-barrier packaging, separate grade campaigns and rigorous end-use screening will hold this business; those competing on catalogue price alone, or tolerating downstream consumer framing, will lose both customers and regulatory goodwill.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Calcium 2-aminoethylphosphate Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Calcium 2-aminoethylphosphate supply chain:

• China — phosphate-ester fine-chemical capacity: Chinese producers supply most commodity-grade material, with established POCl3 handling, aqueous precipitation, ion-exchange and drying trains and the ability to run small custom campaigns quickly. The cluster leads on cost and responsiveness for RUO and catalogue volumes, and leading sites operate ISO 9001 with REACH support through an only representative.
• India — custom synthesis and development-grade campaigns: Indian CDMOs are strongest where the buyer wants a defined development campaign: route selection between chemical and enzymatic phosphorylation, salt-form screening, stoichiometric control, ICH Q7-aligned documentation and full elemental-impurity packages. Their strength is process chemistry and export documentation rather than catalogue logistics.
• European Union and United States — distribution, characterisation and compliance: Western participants dominate the final mile: catalogue distribution, re-packaging under controlled humidity, reference-standard characterisation, RUO labelling and end-use screening. This region also supplies the analytical laboratories that validate the ion-chromatography, LC-MS/MS and 31P-NMR methods buyers rely on.